Senolysis induced by 25-hydroxycholesterol targets CRYAB in multiple cell types

Chandani Limbad1, Ryosuke Doi1, Julia McGirr1

  • 1Buck Institute for Research on Aging, Novato, CA, USA.

Iscience
|February 24, 2022
PubMed

Insights

Researchers identified 25-hydroxycholesterol (25HC) as a novel senolytic drug. This compound effectively clears senescent cells, offering a potential therapeutic strategy for age-related diseases driven by cellular senescence.

Area of Science:

  • Gerontology
  • Molecular Biology
  • Pharmacology

Background:

  • Cellular senescence contributes to age-related diseases.
  • Senolytics are drugs that eliminate senescent cells.
  • Targeting senescence-survival genes is a key senolytic strategy.

Purpose of the Study:

  • Identify novel senescence-induced genes for senolytic targeting.
  • Discover potent senolytic compounds.
  • Validate the senolytic efficacy of identified compounds.

Main Methods:

  • Single-cell RNA sequencing to identify senescence-induced genes.
  • Chemical inhibitor screening for CRYAB disruption.
  • In vitro and in vivo validation of senolytic activity.

Main Results:

  • CRYAB was identified as a robust senescence-induced gene.
  • 25-hydroxycholesterol (25HC) was identified as a potent senolytic agent.
  • 25HC demonstrated senolytic efficacy in human and mouse cells, and in mouse skeletal muscle.

Conclusions:

  • 25HC is a potential senolytic compound targeting CRYAB.
  • 25HC may be a valuable therapeutic for senescent cell-driven pathologies.
  • This discovery opens avenues for new senolytic drug development.